News: Medicine

View:
 

Found press releases

 

REPURCHASE OF SHARES IN ASTRAZENECA PLC

2/9/2012 4:20 AM EST  -   AstraZeneca
Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 20 December 2011 to 8 February 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 477,632 ordinary shares of AstraZeneca PLC at a price of 3001 pence per share on 8 February 2012. Upon the cancellation of these shares, the number of shares in issue will be...

MOBERG DERMA YEAR–END REPORT 2011

2/9/2012 2:00 AM EST  -   MOBERG DERMA AB
STRONG REVENUE GROWTH AND SIGNIFICANTLY IMPROVED EARNINGS
FULL YEAR (JAN-DEC 2011)
•    Net sales MSEK 55.9 (8.5)
•    Research and development expenses MSEK 26.8 (19.0)
•    Operating loss MSEK -7.6 (-30.1)
•    Net loss after tax SEK -6.4 (-31.0)
•    Earnings/loss per share SEK -0.82 (-5.08)
•    Operating cash flow per share SEK -0.99 (-4.97)
•    The board proposes that no dividend will be paid for the...

FURTHER STUDIES MAY BE REQUIRED FOR MOB-015

2/9/2012 1:59 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (OMX: MOB) has analysed data from approximately fifty per cent of the patients in the ongoing open phase II study for MOB-015. Based on the analysis, the company assesses that there is low probability that the final results from the study will be sufficient for out-licensing the project. Further studies will probably be required before continuing to phase III. The ongoing phase II study will be...

DiaGenic reports high 85% accuracy for blood based diagnosis in early Parkinson ...

2/8/2012 11:28 AM EST  -   DiaGenic ASA
The initial findings from DiaGenic sponsored prospective European multicenter Parkinson study is reported. The initial read out of the first subcohort of 79 PD patients and 75 matched healthy controls with no neurodegenerative disease, shows a diagnostic accuracy of 85% in early disease patients while overall accuracy was 88% across all stages.

The preliminary results of the biomarker development program in...

REPURCHASE OF SHARES IN ASTRAZENECA PLC

2/8/2012 4:14 AM EST  -   AstraZeneca
Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 20 December 2011 to 8 February 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 479,101 ordinary shares of AstraZeneca PLC at a price of 2991 pence per share on 7 February 2012. Upon the cancellation of these shares, the number of shares in issue will be...

INTERIM REPORT JANUARY - DECEMBER 2011

2/8/2012 2:30 AM EST  -   Karo Bio
The January–December period and the fourth quarter 2011 in brief

· Net sales amounted to MSEK 0.0 (0.0)
· Net loss was MSEK 226.6 (163.5), whereof the fourth quarter MSEK 50.6 (50.1)
· Loss per share was SEK 0.59 (0.67), whereof the fourth quarter SEK 0.13 (0.20)
· Cash flow from operating activities was MSEK -198.3 (-158.9), whereof the fourth quarter MSEK -37.9 (-44.3). The increase in the full year primarily...

REPURCHASE OF SHARES IN ASTRAZENECA PLC

2/7/2012 6:26 AM EST  -   AstraZeneca
Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 20 December 2011 to 8 February 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 478,287 ordinary shares of AstraZeneca PLC at a price of 2997 pence per share on 6 February 2012. Upon the cancellation of these shares, the number of shares in issue will be...

Presentation of results for fourth quarter 2011

2/7/2012 4:11 AM EST  -   DiaGenic ASA
Presentation of results for fourth quarter 2011 will take place 09:30 (Norwegian time), Tuesday 14 February at Felix Conference Centre, Bryggetorget 3, Aker brygge in Oslo.
The presentation will be available on webcast with the following link:
http://media01.smartcom.no/Microsite/start.aspx?eventid=6605
After the presentation the webcast will be available on demand on the webpage www.diagenic.com under ‘Investor...

REPURCHASE OF SHARES IN ASTRAZENECA PLC

2/6/2012 11:07 AM EST  -   AstraZeneca
AstraZeneca PLC announced that on 3 February 2012, it purchased for cancellation 678,799 ordinary shares of AstraZeneca PLC at a price of 2992 pence per share.

Some of these shares were purchased under the terms of the previously announced irrevocable, non-discretionary share repurchase programme for the period 20 December 2011 to 8 February 2012.

Upon the cancellation of these shares, the number of shares in...

ASTRAZENECA PLC IRREVOCABLE, NON-DISCRETIONARY SHARE REPURCHASE PROGRAMME

2/3/2012 10:25 AM EST  -   AstraZeneca
REPURCHASE OF SHARES IN ASTRAZENECA PLC 2nd AND 3rd FEBRUARY
Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 20 December 2011 to 2 February 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 467,081 ordinary shares of AstraZeneca PLC at a price of 3068 pence per share on 1 February 2012. Upon the...